Abstract
Glucagon like peptide-1 (GLP-1) is one of the gastrointestinal peptides implicated in glycaemic homeostasis. In non-obese individuals with normal glucose tolerance GLP-1 is secreted in response to nutrient intake. However, this GLP- 1 response is generally accepted to be significantly diminished in those with diabetes, obesity or both.
Given that GLP-1 is secreted from enteroendocrine L cells in the intestine, it is not surprising that manipulation of the gastro- intestinal tract has been shown to alter GLP-1 secretion; particularly when this intestinal manipulation is designed to aid weight reduction. GLP-1 dynamics are altered by bariatric surgery, with an improved secretory response to nutrient intake. However, there remains debate on the mechanisms responsible for the alterations in GLP-1 dynamics.
Here we review the evidence for GLP-1 dynamics after Roux-en-Y gastric bpyass (RYGB), adjustable gastric banding (AGB), biliopancreatic diversion (BPD) and sleeve gastrectomy (SG), and make comparisons between modalities. In addition, we review the potential mechanisms underlying these dynamics, other molecules that may add to the “incretin effect” and other possible roles for GLP-1 following bariatric surgery. Finally, we will offer our critique of the evidence base.
Keywords: Bariatric surgery, Glucagon-like peptide-1, GLP-1, Incretins, glucose tolerance, sleeve gastrectomy, Biliopancreatic diversion, adjustable gastric banding, Roux-en-Y gastric bpyass, duodenal switch , homeostasis.
Current Diabetes Reviews
Title:Glucagon Like Peptide-1 (GLP-1) Dynamics Following Bariatric Surgery: A Signpost to a New Frontier
Volume: 9 Issue: 2
Author(s): K. J. Neff, D. O’Shea and C. W. le Roux
Affiliation:
Keywords: Bariatric surgery, Glucagon-like peptide-1, GLP-1, Incretins, glucose tolerance, sleeve gastrectomy, Biliopancreatic diversion, adjustable gastric banding, Roux-en-Y gastric bpyass, duodenal switch , homeostasis.
Abstract: Glucagon like peptide-1 (GLP-1) is one of the gastrointestinal peptides implicated in glycaemic homeostasis. In non-obese individuals with normal glucose tolerance GLP-1 is secreted in response to nutrient intake. However, this GLP- 1 response is generally accepted to be significantly diminished in those with diabetes, obesity or both.
Given that GLP-1 is secreted from enteroendocrine L cells in the intestine, it is not surprising that manipulation of the gastro- intestinal tract has been shown to alter GLP-1 secretion; particularly when this intestinal manipulation is designed to aid weight reduction. GLP-1 dynamics are altered by bariatric surgery, with an improved secretory response to nutrient intake. However, there remains debate on the mechanisms responsible for the alterations in GLP-1 dynamics.
Here we review the evidence for GLP-1 dynamics after Roux-en-Y gastric bpyass (RYGB), adjustable gastric banding (AGB), biliopancreatic diversion (BPD) and sleeve gastrectomy (SG), and make comparisons between modalities. In addition, we review the potential mechanisms underlying these dynamics, other molecules that may add to the “incretin effect” and other possible roles for GLP-1 following bariatric surgery. Finally, we will offer our critique of the evidence base.
Export Options
About this article
Cite this article as:
Neff J. K., O’Shea D. and le Roux W. C., Glucagon Like Peptide-1 (GLP-1) Dynamics Following Bariatric Surgery: A Signpost to a New Frontier, Current Diabetes Reviews 2013; 9 (2) . https://dx.doi.org/10.2174/1573399811309020001
DOI https://dx.doi.org/10.2174/1573399811309020001 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evolution of Exenatide as a Diabetes Therapeutic
Current Diabetes Reviews Beta Cell Regeneration in Adult Mice: Controversy Over the Involvement of Stem Cells
Current Stem Cell Research & Therapy Metabolic Syndrome and Psychiatric Practice: Clinical and Management Issues
Current Psychiatry Reviews Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design Structure Guided Molecular Docking Assisted Alignment Dependent 3DQSAR Study on Steroidal Aromatase Inhibitors (SAIs) as Anti-breast Cancer Agents
Letters in Drug Design & Discovery Umbilical Cord Tissue Mesenchymal Stem Cells: Characterization and Clinical Applications
Current Stem Cell Research & Therapy Early-life Programming of Type 2 Diabetes Mellitus: Understanding the Association between Epigenetics/Genetics and Environmental Factors
Current Genomics The GH/IGF-1 Axis in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Boosting Interleukin-10 Production: Therapeutic Effects and Mechanisms
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Review of Trans-Atlantic Cardiovascular Best Medical Therapy Guidelines – Recommendations for Asymptomatic Carotid Atherosclerosis
Current Vascular Pharmacology Peroxisome Proliferator-Activated Receptor (PPAR) in Regenerative Medicine: Molecular Mechanism for PPAR in Stem Cells’ Adipocyte Differentiation
Current Stem Cell Research & Therapy Atherosclerosis-Related Functions of C-Reactive Protein
Cardiovascular & Hematological Disorders-Drug Targets ACE2 and Diabetic Complications
Current Pharmaceutical Design Metabolic Syndrome in HIV-patients in Antiretroviral Therapy
Current HIV Research The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design Neonatal Diabetes: Applying Molecular Biology to Patient Care
Current Pediatric Reviews The Chemokine System as a Therapeutic Target in Autoimmune Thyroid Diseases: A Focus on the Interferon-γ Inducible Chemokines and their Receptor
Current Pharmaceutical Design Innate Immunity Alterations in Type 2 Diabetes Mellitus: Understanding Infection Susceptibility
Current Molecular Medicine Endothelial Dysfunction and Platelet Hyperaggregation in Type 2 Diabetes Mellitus: The Era of Novel Anti-diabetic Agents
Current Medicinal Chemistry Evaluation of Thiol/Disulfide Homeostasis in Pediatric Patients with Diabetic Ketoacidosis
Combinatorial Chemistry & High Throughput Screening